312 related articles for article (PubMed ID: 11109905)
1. [Current treatment of AL amyloidosis].
Kovacsovics T
Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905
[TBL] [Abstract][Full Text] [Related]
2. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of AL amyloidosis, current data].
Jaccard A
Rev Med Interne; 2006 Nov; 27(11):809-12. PubMed ID: 16934914
[No Abstract] [Full Text] [Related]
5. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of amyloidosis].
Wien TN
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1397-400. PubMed ID: 18552901
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of AL amyloidosis.
Palladini G; Merlini G
Haematologica; 2009 Aug; 94(8):1044-8. PubMed ID: 19644136
[TBL] [Abstract][Full Text] [Related]
9. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
10. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
11. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009 Dec; 16(4):243-5. PubMed ID: 19922338
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
13. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
[TBL] [Abstract][Full Text] [Related]
14. Nephrotic syndrome secondary to amyloidosis.
Kneipp S; Himmelstein SB
Nurse Pract; 2000 Jun; 25(6 Pt 1):78, 81, 85-6 passim. PubMed ID: 10884998
[TBL] [Abstract][Full Text] [Related]
15. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M
Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787
[TBL] [Abstract][Full Text] [Related]
16. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic approaches in primary systemic AL amyloidosis.
Sezer O; Eucker J; Schmid P; Possinger K
Ann Hematol; 2000 Jan; 79(1):1-6. PubMed ID: 10663614
[TBL] [Abstract][Full Text] [Related]
18. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
19. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.
Comenzo RL; Vosburgh E; Simms RW; Bergethon P; Sarnacki D; Finn K; Dubrey S; Faller DV; Wright DG; Falk RH; Skinner M
Blood; 1996 Oct; 88(7):2801-6. PubMed ID: 8839879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]